Physician profile
Christopher M Duma
NPI 1306870845
$142,231.40
in general payments reported to CMS, 2019-2025
32 companies · $117K in 2025
The $117K reported for 2025 was more than what 98% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,978 · 2020: $2,909 · 2021: $12K · 2022: $982 · 2023: $2,458 · 2024: $3,185 · 2025: $117K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $114K · Food and Beverage: $9,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $113,748.80 |
| Food and Beverage | $9,321.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Longeviti Neuro Solutions INC | $126,111.09 | 2021-2025 | Clearfit |
| Medtronic, INC. | $5,986.35 | 2021-2025 | Activa PC, Stealthstation S8 Platform, Aquamantys(Tm) |
| Osteomed LLC | $2,784.10 | 2019-2020 | |
| Medtronic USA, INC. | $1,642.20 | 2019-2020 | |
| Boston Scientific Corporation | $763.33 | 2019-2025 | General - Dbs |
| Insightec,INC | $642.04 | 2024-2025 | Exablate |
| Nx Development Corp. | $638.87 | 2019-2021 | |
| Abbott Laboratories | $631.76 | 2019-2025 | Infinity, Eterna, Penta |
| Visionrt, INC. | $523.34 | 2019 | |
| Surgical Theater. INC. | $317.26 | 2025 | |
| Ucb, INC. | $311.64 | 2024-2025 | Briviact, Nayzilam |
| Lilly USA, LLC | $269.99 | 2024-2025 | Kisunla, Amyvid |
| Aesculap, INC. | $213.98 | 2019-2024 | Xabo Antimicrobial Shunt Catheter, M.Blue |
| Zap Surgical Systems, INC. | $201.15 | 2023 | Zap-X Mv Imager, Zap-X Treatment Delivery Software, Zap-X Treatment Planning Software |
| Monteris Medical Corporation | $185.00 | 2025 | Neuroblate |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $128.45 | 2022-2023 | Botox |
| Stryker Corporation | $97.71 | 2019-2020 | |
| Gt Medical Technologies, INC | $96.75 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $87.23 | 2023-2024 | Welireg, Keytruda |
| Novocure INC. | $84.26 | 2019 | |
| Irras USA, INC. | $78.39 | 2022 | |
| Arbor Pharmaceuticals, INC. | $77.41 | 2019-2021 | |
| Integra Lifesciences Corporation | $75.22 | 2021-2025 | Codman Certas, Codman Hakim, Cusa Clarity |
| Cerapedics INC. | $50.64 | 2021 | |
| Elekta, INC. | $44.54 | 2021 | |
| Terumo Bct, INC. | $43.54 | 2020 | |
| Ethicon US, LLC | $37.00 | 2024 | Surgiflo Hemostatic Matrix, Echelon Endopath, Echelon Flex |
| Allergan, INC. | $31.77 | 2021-2022 | |
| Biogen, INC. | $28.30 | 2025 | Leqembi |
| Analogic Corporation | $25.43 | 2019 | |
| Lemaitre Vascular, INC. | $14.82 | 2019 | |
| Kls-Martin L.P. | $7.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$0.01 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Duma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.